Pharmagreen Biotech (Pharmagreen Biotech) Equity-to-Asset

: -15.03 (As of Jun. 2023)

View and export this data going back to 2008. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Pharmagreen Biotech's Total Stockholders Equity for the quarter that ended in Jun. 2023 was $-2.10 Mil. Pharmagreen Biotech's Total Assets for the quarter that ended in Jun. 2023 was $0.14 Mil. Therefore, Pharmagreen Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was -15.03.

The historical rank and industry rank for Pharmagreen Biotech's Equity-to-Asset or its related term are showing as below:

PHBI' s Equity-to-Asset Range Over the Past 10 Years
Min: -130.29 Med: -7.14 Max: -1.21
Current: -15.03

During the past 7 years, the highest Equity to Asset Ratio of Pharmagreen Biotech was -1.21. The lowest was -130.29. And the median was -7.14.

PHBI's Equity-to-Asset is ranked worse than
98.9% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs PHBI: -15.03

Pharmagreen Biotech Equity-to-Asset Historical Data

The historical data trend for Pharmagreen Biotech's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmagreen Biotech Annual Data

Trend

Apr08

Apr09

Sep18

Sep19

Sep20

Sep21

Sep22

Equity-to-Asset

-3.09

-1.32

-10.86

-4.41

-8.50

Pharmagreen Biotech Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Equity-to-Asset																-9.90	-8.50	-8.26	-11.91	-15.03

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmagreen Biotech's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmagreen Biotech Equity-to-Asset Distribution

For the Drug Manufacturers industry and Healthcare sector, Pharmagreen Biotech's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Pharmagreen Biotech's Equity-to-Asset falls into.

Pharmagreen Biotech Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Pharmagreen Biotech's Equity to Asset Ratio for the fiscal year that ended in Sep. 2022 is calculated as

Equity to Asset (A: Sep. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	-1.776	/	0.209
	=

Pharmagreen Biotech's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	-2.104	/	0.14
	=	-15.03

Pharmagreen Biotech (OTCPK:PHBI) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Pharmagreen Biotech Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Pharmagreen Biotech's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharmagreen Biotech (Pharmagreen Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmagreen Biotech Inc (OTCPK:PHBI) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

112 North Curry Street, Carson, NV, USA, 89703

Website

https://www.pharmagreen.ca

Pharmagreen Biotech Inc is a biotech science company with specialized products and services in the cannabis industry. The company plans to produce and sell tissue culture plantlets and cannabis oil. Its line of nutraceutical products is a proprietary blend of therapeutic plants and mushrooms. It is developing its business model beyond just cannabis, and is focused on near term revenues from its proprietary blend of therapeutic plants and fungi, a nutraceutical wellness product. Utilizing the Company's expertise in plant genetics, Its transgenic program uses the newest technology available to research and create nutraceuticals, protein-based vaccines, and daily supplements with the potential to improve lives and address a wide variety of disease conditions.